Adimmune, your trusted partner to global market
We tailor our services to customers’ needs and offer solutions for various scales, phases, and timelines. We are one of the key suppliers of high-quality vaccines and biologics around the world.
View All
Support Resilient
Supply for Vaccines
We engage with the WHO Pandemic Influenza Preparedness Framework to foster the development and access to vaccines. Recognized by US FDA and the EU, we tackle health challenges by leveraging our high standards of quality.
21 Oct. 2025
Adimmune Group Vaccines Listed in WHO Full Vaccine Product List
Adimmune Corporation (TWSE:4142) today announced that three of its vaccines—the seasonal influenza vaccine, tetanus toxoid vaccine, and the enterovirus 71 (EV71) vaccine developed by its subsidiary Enimmune—are now officially listed in the World Health Organization (WHO) Full Vaccine Product List published in September. Inclusion in the WHO list signifies that Adimmune has entered the global public health supply chain, marking a significant milestone for Taiwan’s vaccine industry as its quality and manufacturing capabilities gain recognition from the global health community.
30 Sep. 2025
Adimmune and Enimmune Rush 5,000 Doses of Tetanus Vaccine to Hualien Disaster Zone
Adimmune Corporation (4142) announced today that, in coordination with the Taiwan Centers for Disease Control (CDC) and the Hualien County Health Bureau, it has urgently delivered 5,000 doses of tetanus vaccine to Guangfu Township in Hualien, where residents and volunteers are working intensively on post-disaster cleanup. The donation aims to protect both disaster victims and relief workers from tetanus infections caused by injuries sustained in debris-laden flood zones.
26 Aug. 2025
ANVISA’s GMP Certification Granted to Adimmune Significantly Advances the Progress toward Regulatory Approval in Brazil
Adimmune Corporation (4142) today announced that its Tanzi plant in Taichung has officially received Good Manufacturing Practice (GMP) certification from the Brazilian Health Regulatory Agency (ANVISA). The certification follows an on-site inspection conducted in June, during which ANVISA officials reviewed Adimmune’s influenza vaccine production process.
